The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

BACKGROUND: T-cell checkpoint blockade and MEK inhibitor combinations are under clinical investigation. Despite progress elucidating the immuno-modulatory effects of MEK inhibitors as standalone therapies, the impact of MEK inhibition on the activity of T-cell checkpoint inhibitors remains incomplet...

Descripción completa

Detalles Bibliográficos
Autores principales: Poon, Edmund, Mullins, Stefanie, Watkins, Amanda, Williams, Geoffrey S., Koopmann, Jens-Oliver, Di Genova, Gianfranco, Cumberbatch, Marie, Veldman-Jones, Margaret, Grosskurth, Shaun E., Sah, Vasu, Schuller, Alwin, Reimer, Corrine, Dovedi, Simon J., Smith, Paul D., Stewart, Ross, Wilkinson, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557252/
https://www.ncbi.nlm.nih.gov/pubmed/28807001
http://dx.doi.org/10.1186/s40425-017-0268-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557252/
https://www.ncbi.nlm.nih.gov/pubmed/28807001
http://dx.doi.org/10.1186/s40425-017-0268-8

Ejemplares similares